Published in Gynecol Oncol on November 01, 1992
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) 5.68
The interferons. Mechanisms of action and clinical applications. JAMA (1991) 2.68
Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol (2005) 2.46
Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet (1995) 2.36
Human herpesvirus 8 DNA sequences in blistering skin from patients with pemphigus. Arch Dermatol (1997) 2.12
Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol (1997) 2.08
Cutaneous and subcutaneous endometriosis. Surgical and hormonal therapy. J Dermatol Surg Oncol (1994) 1.82
A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med (1996) 1.73
Reactivation and shedding of cytomegalovirus in astronauts during spaceflight. J Infect Dis (2000) 1.59
Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother (1998) 1.47
An outbreak of lindane-resistant scabies treated successfully with permethrin 5% cream. J Am Acad Dermatol (1991) 1.43
Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol (2003) 1.42
Verrucous cyst. Arch Dermatol (1991) 1.40
A decrease from 8 to 6 weeks in obstetrics and gynecology clerkship: effect on medical students' cognitive knowledge. Obstet Gynecol (1995) 1.39
Varicella zoster virus. J Am Acad Dermatol (1999) 1.38
Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope (1998) 1.29
Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med (2000) 1.27
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res (1999) 1.24
p53 mutations in basal cell carcinomas. Cancer Res (1992) 1.21
Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res (1996) 1.15
Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis (2007) 1.12
Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol (1997) 1.12
Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med (1997) 1.09
Enterobius vermicularis salpingitis: a distant episode from precipitating appendicitis. Obstet Gynecol (1992) 1.09
An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol (2000) 1.09
Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol (1988) 1.08
Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest (1998) 1.07
Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology. Invest Ophthalmol Vis Sci (1997) 1.03
Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi's sarcoma and other lesions. J Mol Med (Berl) (1995) 1.03
Combined Epstein-Barr virus and human papillomavirus infection in nasopharyngeal carcinoma. Laryngoscope (1998) 1.02
Endometriosis occurring in leiomyomatosis peritonealis disseminata: ultrastructural study and histogenetic consideration. Am J Surg Pathol (1980) 0.99
Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet (1999) 0.98
Human papillomavirus, smoking, and cancer. J Cutan Med Surg (2001) 0.98
Omenn's syndrome and related combined immunodeficiency syndromes: diagnostic considerations in infants with persistent erythroderma and failure to thrive. J Am Acad Dermatol (1991) 0.97
Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis (2006) 0.97
A rare case of disseminated cutaneous zoster in an immunocompetent patient. BMC Fam Pract (2005) 0.97
Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis (1990) 0.97
Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol (1999) 0.96
Incidence of Epstein-Barr virus in astronaut saliva during spaceflight. Aviat Space Environ Med (1999) 0.96
The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Arch Dermatol (1997) 0.95
Herpesvirus-like DNA sequences in classic Kaposi's sarcomas. J Med Virol (1995) 0.95
The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol (2007) 0.95
Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. Transplantation (1999) 0.94
Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions. Sex Transm Dis (1997) 0.92
Failure of the polymerase chain reaction (PCR) to detect human papilloma virus (HPV) in transitional cell carcinoma of the bladder. Anticancer Res (1993) 0.92
Monitoring populations for DNA repair deficiency and for cancer susceptibility. Environ Health Perspect (1996) 0.92
Occurrence of human papillomavirus and p53 gene mutations in Kaposi's sarcoma. Virology (1994) 0.92
Production of interferon gamma messenger RNA by cells of non-immune origin. Cytokine (1995) 0.91
Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis (2001) 0.91
Interleukin-10 messenger ribonucleic acid in human placenta: implications of a role for interleukin-10 in fetal allograft protection. Am J Obstet Gynecol (1995) 0.91
Zinc-alpha(2)-glycoprotein hinders cell proliferation and reduces cdc2 expression. J Cell Biochem Suppl (2001) 0.91
Detection of human herpesvirus-8 DNA in Kaposi's sarcomas from iatrogenically immunosuppressed patients. J Am Acad Dermatol (1998) 0.90
Crusted (Norwegian) scabies in patients with AIDS: the range of clinical presentations. South Med J (1994) 0.90
Recombinant desmoglein 3 has the necessary epitopes to adsorb and induce blister-causing antibodies. J Invest Dermatol (1996) 0.90
Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatol Venereol (2007) 0.90
Genital warts and their treatment. Clin Infect Dis (1999) 0.90
Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Therapy Lett (2010) 0.89
Strain differences in production of murine interferons. Proc Soc Exp Biol Med (1980) 0.89
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrob Agents Chemother (2000) 0.89
Diminished interferon gamma production may be the earliest indicator of infection with the human immunodeficiency virus. Viral Immunol (1989) 0.88
Novel therapy for the treatment of human carcinoid. Ann Surg (1991) 0.88
Verrucous carcinoma of the foot associated with human papillomavirus type 16. J Am Acad Dermatol (2001) 0.88
Development of human papillomavirus type 16 associated squamous cell carcinoma of the scrotum in a patient with Darier's disease treated with systemic isotretinoin. J Urol (1995) 0.88
Iatrogenic contamination of multidose vials in simulated use. A reassessment of current patient injection technique. Arch Dermatol (1990) 0.88
Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med (1997) 0.87
Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy. J Am Acad Dermatol (1997) 0.87
Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol (1997) 0.87
Hemorrhagic bullae associated with Vibrio vulnificus septicemia. Report of two cases. Arch Dermatol (1986) 0.86
Benign Leydig cell tumor of the testis associated with human papillomavirus type 33 presenting with the sign of Leser-Trélat. J Urol (1993) 0.86
Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors. Cancer Lett (1999) 0.86
Fatal septicemia and bullae caused by non-01 Vibrio cholerae. J Am Acad Dermatol (1993) 0.86
Isoforms of cathepsin D and human epidermal differentiation. Biochimie (1998) 0.85
Chromosomal radiosensitivity of lymphocytes from skin cancer-prone patients. Mutat Res (1995) 0.85
The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care (1999) 0.85
Conditioned enhancement of natural killer cell activity, but not interferon, with camphor or saccharin-LiCl conditioned stimulus. J Neurosci Res (1987) 0.85
High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus. J Med Virol (1998) 0.85
Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response. J Med Virol (1993) 0.85
Famciclovir: review of clinical efficacy and safety. Antiviral Res (1996) 0.84
An overview of sexually transmitted diseases. Part I. J Am Acad Dermatol (1999) 0.84
Patients with condyloma acuminatum exhibit decreased interleukin-2 and interferon gamma production and depressed natural killer activity. J Clin Immunol (1987) 0.84
Skin-associated lymphoid tissue in human immunodeficiency virus-1, human papillomavirus, and herpes simplex virus infections. J Invest Dermatol (1995) 0.84
Nonsunlight risk factors for malignant melanoma. Part I: Chemical agents, physical conditions, and occupation. Int J Dermatol (1994) 0.84
Immortalization of differentiated human keratinocytes by human papillomavirus (HPV) 16 DNA. J Dermatol Sci (1996) 0.84
Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res (2001) 0.84
Cytokines modulate terminal differentiation and the expression of predesquamin in cultured keratinocytes. Exp Cell Res (1994) 0.83
Safety, efficacy & recurrence rates of imiquimod cream 5% for treatment of anogenital warts. Skin Therapy Lett (2009) 0.83
Characterization of zinc-alpha(2)-glycoprotein as a cell adhesion molecule that inhibits the proliferation of an oral tumor cell line. J Cell Biochem (1999) 0.83
Morphological and immunohistochemical characteristics of dimethylnitrosamine-induced malignant mesenchymal renal tumor in F-344 rats. J Cancer Res Clin Oncol (1990) 0.83
Tumor differentiation-dependent local immunity in human head and neck cancers. Cancer Lett (1998) 0.83
Induction of blister-causing antibodies by a recombinant full-length, but not the extracellular, domain of the pemphigus vulgaris antigen (desmoglein 3). J Immunol (1996) 0.83
Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway. Antiviral Res (1994) 0.83
Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg (1994) 0.83
Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS (1998) 0.83
Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J Sci Am (2006) 0.83
Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A-->T polymorphism in the TMC8/EVER2 gene. Dermatology (2008) 0.83